



A V E X A

AGM 2016

Presentation by

Iain Kirkwood (Chairman)

29th November 2016

Agenda

- Company Highlights
- Vision and Strategy
- Corporate Overview
- Business Update
- Disclaimer



Company Highlights

- TALI-Train (Generation 0.1) enters pre-commercialisation product testing with selected clinics
- Monash University utilises TALI platform in a large school-based research trial involving approximately 120 children to strengthen and evolve the TALI platform
- TALI-Detect enters early stage research phase in collaboration with Monash University
- 1 for 1 Non-Renounceable Rights Issue raised \$2.2m in July 2017
- Cost reduction program initiated with benefits to flow into FY17
- Undertaking a sale of ordinary shares for shareholders who hold less than a marketable parcel



Vision and Strategy

- Avexa seeks shareholder approval to change its name to Novita Healthcare Limited
- Novita is Italian for Innovation – **“Innovation in Healthcare”**
- The vision for the company is to position itself at the forefront of innovative medical technologies with TALI as the foundation product for the future.
- Novita will continue to focus on commercialisation of TALI Train and the research of TALI Detect
- Novita will simultaneously seek alternative investment opportunities to capitalise on innovative medical technologies as it seeks to build a sustainable and viable business model for shareholders



Corporate Overview

Financial Information	
Share price (22 nd Nov-2016)	2.5c
Number of shares (m)	204.84
Market Capitalisation	\$5.1m
Cash (31-Oct-16)	\$1.9m

Source: IRESS

Top Shareholders	%
Megabay Holdings	9.29
Grey Innovation Holdings	6.38



Board of Directors



Mr Iain Kirkwood
Non-Executive Chairman



Mr Jefferson Harcourt
Non-Executive Director



Mr Mark Simari
Non-Executive Director



Professor Kim Cornish
Chair – TALI Scientific
Advisory Board



Business Update

- Divestment of Chusa (North Pratt Coal Mine) Investment commenced
- ATC responsibilities in the process of being handed back to Shire
- Hannah Kirk becomes Chief Research Officer
- Currently in discussions to add the following resources to the company's executive team:
 - Business Development Manager – to assist with the ramp up to TALI commercialisation
 - Project Manager – to guide the company through its next phases of research and development



2016 Annual General Meeting Presentation

Thank You



DISCLAIMER

Some of the statements in this presentation constitute “forward-looking statements” that do not directly or exclusively relate to historical facts.

These forward-looking statements reflect Avexa Limited’s current intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors, many of which are outside Avexa Limited’s control. Important factors that could cause actual results to differ materially from the expectations expressed or implied in the forward-looking statements include known and unknown risks.

Because actual results could differ materially from Avexa Limited’s current intentions, plans, expectations, assumptions and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

